2021 ENVIRONMENTAL SOCIAL & GOVERNANCE REPORT
Contents

ABOUT US
ESG PROGRAM
AMICUS HEADQUARTERS
ENVIRONMENTAL MANAGEMENT
OUR FACILITIES
OUR CULTURE
CEO ACTION PLEDGE
HEALING BEYOND DISEASE
PHILANTHROPY: CHARITABLE GIVING AT AMICUS
TIME, TALENT, TREASURE
HUMAN CAPITAL MANAGEMENT
ACCESS AND PRICING PROMISE
COVID-19 RESPONSES
OUR AWARDS
GOVERNANCE, RISK, AND COMPLIANCE
OUR ENTERPRISE RISK PROGRAM
OUR COMMITMENT
SAFE HARBOR
Amicus, the Latin word for friend, signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. This spirit of empathy, compassion, and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge technologies.

We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with a range of rare and devastating diseases. Each program that we invest in must have three key characteristics:

- Address a rare genetic disease or a life-limiting disorder
- Have the potential to be first-in-class or best-in-class
- Impart a meaningful benefit for patients as defined by those living with a rare disease and their caregivers

"Every biotech company is focused on patients, but at Amicus we do it differently; we first consider the needs of patients in everything we do."
Our dedication to patients goes hand in hand with our commitment to our environmental, social, and governance responsibilities. Building strong ESG practices and oversight into our scientific and business activities creates a culture of integrity at every level of the organization, while safely and effectively delivering on our founding beliefs — be at the forefront of therapies for rare and orphan diseases, create long-term value for our stakeholders, and foster teamwork and respect for individual contributions.

Our foundational ESG program reflects the effective management of critical environmental, social, and governance principles that are fundamental to our organization. Our ESG initiatives, which are consistent with those identified by the Sustainability Accounting Standards Board (SASB) for the biotechnology and pharmaceuticals sector, serve as a broad guide for our report content.

The discovery, development, and delivery of important medicines and therapies to patients, clinical, and regulatory activity, employee engagement, and responsibility to our investors are underscored by our commitment to sustainable growth for all stakeholders. It is our belief that a sound governance structure, coupled with a socially and environmentally responsible mindset, provides the foundation for collective decision making and accountability across all facets of Amicus. Evolving our ESG program and its initiatives is a key goal for Amicus, and we look forward to reporting additional data and metrics relative to our ongoing progress on an annual basis.
Our global headquarters and our Global Research and Gene Therapy Center of Excellence is located in Philadelphia, PA, in a state-of-the-art facility that redefines the paradigm of the typical research space. Located in a burgeoning hub for medical breakthroughs, this facility advances our industry-leading portfolio of rare disease gene therapy programs, and was developed with environmentally responsible design principles in mind.

AMICUS GLOBAL HEADQUARTERS: PHILADELPHIA, PA

In the build-out of the UK facility, our key partners sustainably sourced design elements including flooring, carpeting, furniture, and fixtures. In addition, special emphasis on carbon footprint reduction was achieved with numerous recycling features including a decrease in printers throughout the space to reduce the amount of paper waste.

AMICUS INTERNATIONAL HEADQUARTERS: MARLOW, UK

A reduction in our physical facilities and an increase in our remote work capacity has positioned us well for a post-COVID business environment. Our eco-friendly decision-making has unearthed economic efficiencies while continuing to bolster our standing as a good corporate citizen.
Our Philadelphia Corporate Headquarters

**Green Building Design**
- Redesigned electrical systems for optimal performance and sustainability
- Installed green roof for optimal efficiency benefits; provides evaporation and delayed water drainage to sewer system
- Low-emitting materials installed throughout the building, with 20% use of recycled materials
- 100% Energy Star equipment and occupancy sensors; automatic lighting shutoff controls help lower energy use

**Energy & Water Conservation**
- High efficiency water fixtures
- High efficiency mechanical and laboratory equipment
- Daylight and motion sensors allow full spectrum of natural light; LED fixtures used only when necessary
- 20% energy savings by using VAV system with return air; energy recovery units provide air for both high performing labs and offices
- High efficiency windows reduce solar heat gain

**Hazardous Waste Management**
- Approximately 75% of construction and demolition waste diverted from landfills and/or incineration
- All hazardous materials stored on first floor and transferred to labs via service elevator adhering to strict environmental building codes
- Washroom and 600 square foot nitrogen generation system designed to manage lab waste before transport through service elevator
Our Focus on Sustainable Operations Begins with Our Own Facilities

Everything that we do at Amicus, we do with the highest standards in mind. This includes how we design and develop the Amicus facilities we occupy – fully integrated to support both the cutting-edge technology that allows us to deliver on our mission for the communities we serve, while reducing our impact on the environment. It also includes where and how we work. For example, we closed our former global headquarters and are planning for a smaller footprint and a mixed on-site and virtual model. Our present and future facilities are founded on environmentally responsible design principles. As we designed our current spaces and as we move forward with new opportunities, we will look to continue to meet and exceed all building standards currently set. With each new building technology introduced, we evaluate it to see how it can benefit our workforce, the environment, and our business. Amicus recognizes that we must hold ourselves accountable to ensure that we are doing our part in preserving the future of our planet, as well as improving the workplace environment.

Amicus Partners are Committed to Improving Green Credentials

Our business activities are conducted in a manner that protects the health and safety of our employees, minimizes the environmental impacts of our operations, promotes effective stewardship of environmental resources, and maintains a steadfast focus on product quality and safety.

Amicus Global Technical Operations is committed to improving Green credentials through our supply chain partners to reduce environmental impact. We are partnering with our manufacturing vendors to manage the carbon footprint that is a result of the processes used to manufacture our products. Together with our partners, we are aligned in our approach and have ESG as a standing agenda item in our Quarterly Business Reviews. Throughout 2021 and beyond, we will assess the progress of these programs and partners to help drive change. We will also consider the environmental impact on any/all future proposal submissions.
At Amicus, our goal is to develop an employee-driven atmosphere where employees can contribute to winning teams, lead important and meaningful initiatives, and be inspired by a diverse group of talented leaders and colleagues.

Diversity, Equity, and Inclusion (DEI) at Amicus is about creating a setting that supports bringing the authentic “you” to the workplace. Our unique experiences, backgrounds, and range of cultural perspectives enrich how we approach opportunities, pushing ideas as far and as fast as possible with patients always our top priority. Employee expertise, intelligence, and creativity drives our innovation, and our passion and commitment to excellence.

Our “Three Pillars of DEI” are interwoven into our Amicus culture and expand one person, one word, and one act at a time. For our employees, these three pillars are a touchstone for inspiration, guidance, and encouragement.

Our transparent, inclusive, and collaborative culture gives employees the tools and resources to grow personally and professionally while ensuring we can meaningfully engage with the global rare disease patient community. We are committed to giving back to the communities where our employees live and work through volunteer opportunities, charitable contributions, and connecting with individuals and families affected by serious illnesses. As a part of Amicus’ personal commitment to diversity, equity, and inclusion in the workplace, we have identified bold, yet attainable goals intended to strengthen our culture of inclusivity, while enabling us to deliver on our mission for patients.

- Embed DEI into activities of our business units, the Amicus Belief Statement, and Mission-Focused Behaviors
- Ensure diverse representation in next generation talent initiatives
- Attract talent through a diverse lens (candidate slates, interview teams, inclusive hiring processes)
- Ensure diversity in Board of Directors and Senior Leadership Team representation
- Ensure diverse representation in our clinical trials
- Create patient education to impact health literacy
- Address the impact of socioeconomics and access through advocacy
- Work towards global access to treatments for patients
- Support non-profits that impact diverse communities
- Invest in the next generation of innovators through partnerships with STEM programs
- Build awareness of rare diseases in diverse populations
CEO ACTION PLEDGE

THE PLEDGE

In July 2020, John F. Crowley, our Chairman and Chief Executive Officer, signed the CEO Pledge, together with leaders of multiple domestic and international companies, to advance diversity and inclusion in the workplace.

THE PLEDGE

We pledge to support a more inclusive culture to impact our employees, our communities, and society.

TAKING ACTION

The Pledge outlines a specific set of actions that companies will take to cultivate a trusting environment where all ideas are welcome, and employees feel comfortable and empowered to discuss diversity and inclusion. In support of the Pledge, amongst other actions, Amicus introduced goals to increase diversity, equity, and inclusion, and launched Employee Resource Groups; voluntary, employee-led groups designed to foster a diverse and inclusive workplace aligned with the organizations they serve.

Beginning in 2021:

✓ Strengthen our culture of inclusivity by delivering on our diversity, equity, and inclusion programs
✓ Ensure diverse hiring slates for all roles, increasing the number of diverse hires, especially for Director and above positions
✓ Retain existing diverse talent

HOLISTIC APPROACH

Recognizing that diversity and inclusion are multifaceted issues, tackling these issues holistically increases better engagement and support for all underrepresented groups within business. To do this, we believe in addressing the concerns and needs of our diverse employees honestly and head-on, which will increase equity for all including Blacks, Latinos, Asians, Native Americans, LGBTQ, women, and people with disabilities.

2023 and Beyond:

✓ Maintain strength in global gender diversity
✓ Increase U.S. diversity through intentional and ongoing action
✓ Continuously evaluate compensation practices to ensure pay parity
An educational mainstay since the earliest days of the company, we launched the Lunch & Learn series. This longstanding commitment to educate and inspire Team Amicus was incorporated into Healing Beyond Disease to amplify our care, connection, and compassion for the rare disease community.

9 Lunch & Learns/webcasts were presented in 2020:

**Lunch & Learns:** 2020 Rare Disease Day; Coping in an Uncertain World: Two Disabled Dudes; Mothers and Sons Living with Fabry: A Conversation in Honor of Mother’s Day; Engagement, Research, and Treatment: Connecting to a Diverse Rare Disease Community; One Year to Live, 25 Years Later: The Power of Gratitude*

* These titles represent 5 of the 9 L&Ls presented in 2020

**HBD Talent roundtables:** We conducted four roundtables with individuals, patient organizations, and small private companies in research areas that aren’t specific to Amicus. Through interactive Q&A, Amicus employees provide information that may be helpful as these individuals look to advance their research, disease knowledge, and mission of their organization.

The HBD Lunch & Learns have become an important event woven into the corporate culture of Amicus. Recent programs discussing the role of newborn screening in ensuring early and appropriate treatment of diagnosed rare diseases, and how clinical trials testing new medicines represent the full diversity of the rare diseases community, bring home the importance of the work being accomplished at Amicus.
### PHILANTHROPY: CHARITABLE GIVING

<table>
<thead>
<tr>
<th>U.S. Contributions</th>
<th>International Contributions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total number of contributions</strong></td>
<td><strong>82</strong></td>
</tr>
<tr>
<td><strong>Total amount of contributions allocated</strong></td>
<td><strong>$1,750,386</strong></td>
</tr>
<tr>
<td><strong>Total amount given to rare disease Patient Advocacy Organizations (PAOs)</strong></td>
<td><strong>$994,000</strong></td>
</tr>
<tr>
<td><strong>Total amount given to community non-profits and non disease-specific PAOs, e.g., HomeFront NJ homelessness relief and BioNJ</strong></td>
<td><strong>$321,677</strong></td>
</tr>
<tr>
<td><strong>COVID-19-related charitable support 2H20</strong></td>
<td><strong>$23,500</strong></td>
</tr>
<tr>
<td>to 4 non-profits</td>
<td>to 3 non-profits</td>
</tr>
<tr>
<td><strong>Total amount given to 2 non-profits</strong></td>
<td><strong>$28,900</strong></td>
</tr>
<tr>
<td></td>
<td><strong>U.S.</strong></td>
</tr>
<tr>
<td><strong>Total number of countries in which Amicus made charitable contributions</strong></td>
<td><strong>22</strong></td>
</tr>
<tr>
<td><strong>Australia</strong></td>
<td><strong>Ireland</strong></td>
</tr>
<tr>
<td><strong>Austria</strong></td>
<td><strong>Italy</strong></td>
</tr>
<tr>
<td><strong>Belgium</strong></td>
<td><strong>Japan</strong></td>
</tr>
<tr>
<td><strong>Brazil</strong></td>
<td><strong>New Zealand</strong></td>
</tr>
<tr>
<td><strong>Canada</strong></td>
<td><strong>Netherlands</strong></td>
</tr>
<tr>
<td><strong>Czech Republic</strong></td>
<td><strong>Poland</strong></td>
</tr>
<tr>
<td><strong>Denmark</strong></td>
<td><strong>Spain</strong></td>
</tr>
<tr>
<td><strong>France</strong></td>
<td><strong>Sweden</strong></td>
</tr>
<tr>
<td><strong>Finland</strong></td>
<td><strong>Switzerland</strong></td>
</tr>
<tr>
<td><strong>Germany</strong></td>
<td><strong>UK</strong></td>
</tr>
<tr>
<td><strong>Greece</strong></td>
<td><strong>U.S.</strong></td>
</tr>
<tr>
<td><strong>Hungary</strong></td>
<td>****</td>
</tr>
</tbody>
</table>
Since its founding, Healing Beyond Disease has supported employees in contributing to the causes they care about:

<table>
<thead>
<tr>
<th>3,000+ hrs</th>
<th>50+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volunteer hours logged by U.S. employees</td>
<td>Community support programs in which Team Amicus has participated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>$15,000+</th>
<th>$9,000+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated by U.S. employees</td>
<td>Corporate-matched donations in addition to charitable contributions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>20+</th>
<th>52 in 18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formal HBD roundtable collaborations</td>
<td>Patients Countries</td>
</tr>
</tbody>
</table>

*Each roundtable involves multiple volunteers who work with early-stage organizations on an ongoing basis

Expanded Access in 2020: delivering our therapies to patients in need at no charge
HUMAN CAPITAL
AT AMICUS

We strive to have a meaningful impact on organizational performance and enable a competitive advantage through our people. We have almost 500 employees across the U.S. and select international countries who are key to advancing our programs and who contribute to our culture of passion, dedication, and excitement for the work that we do.

Our Board of Directors and senior management are committed to our broad human capital philosophies, practices, and risk management to create value and support our mission. Attracting and retaining talented team members, and creating a viable and consistent work experience, is an integral part of our competitive strategy driving long-term value and risk mitigation. To that end, the Compensation and Leadership Development Committee and the full Board review our key human capital programs and processes on a regular basis, including our talent pipeline, turnover, workplace culture, inclusion and engagement, and workforce risk. In addition, certain goals on maintaining gender diversity and increasing overall diversity and culture are embedded in our corporate and individual goals and reinforced through our compensation management decisions.
In 2019, building on our founding beliefs, we put in place Mission-Focused Behaviors to define and shape culture, drive performance and innovation, inform development and growth, and attract and retain the best talent. This was transformational for our culture, leading to advancements in design thinking and growth mindset.

We also launched our **Mission-Focused Behaviors Roadshow** at Amicus through extensive employee-driven workshops that shifted from traditional thinking and:

- Embedded the leadership traits of our culture (mission, integrity, performance, and innovation)
- Altered the way we conduct performance management with these common drivers as the foundation
- Shifted to Objectives & Key Results (OKR) management, including establishing a feedback culture to drive results, and a fair measurement process that captures performance data

**LED FROM WITHIN: REDISCOVER, REIMAGINE, AND REINVENT**

We empowered employees to lead our efforts to Rediscover, Reimagine, and Reinvent Amicus by developing prototypes that can be tested and implemented on a large scale across the company and which will position us well for the future.
PRICING PROMISE AND COMMITMENT TO PATIENTS

At Amicus Therapeutics, we believe that the life sciences industry and the people we serve need bold leaders and responsible innovators. Our Amicus Pricing PROMISE reflects our corporate belief that “our medicines must be fairly priced and broadly accessible”, and includes our promise to price our products at or below parity to competitive products and not to raise the price for any Amicus medicine annually more than the Consumer Price Index (CPI).

Pricing our medicines responsibly should serve people and reward innovation while delivering stakeholder returns. With a duty to obsolete our own technologies and continue to serve our rare disease communities, we have also pledged to reinvest a portion of our revenues from approved treatments into research and development for the same diseases until there is a cure.
Our Patients

Amicus committed to provide uninterrupted access to medicines for those who needed treatments.

- **Global supply chains for Galafold® (migalastat)** were not interrupted and continued to supply the medicine for people living with Fabry disease with amenable variants even in the most impacted areas
- **Participants enrolled in all clinical studies** for AT-GAA for Pompe disease, including the Phase 3 PROPEL study, continued to receive study drug with the study completed on time
- **Each patient and clinical site had individual plans** to ensure access to the study drug and completion of trial-related assessments

Amicus reinforced and elevated communications, as well as the resources provided to patient community partners.

Our People

Following the emergence of the COVID-19 pandemic, Amicus aligned with public health strategies and rapidly put in place a comprehensive response to help prevent the spread of COVID-19 to our global workforce. An employee engagement strategy was quickly implemented to keep employees safe, informed, and motivated.

- **Donated thousands of masks, gloves, and other supplies** from our Philadelphia Center of Excellence to organizations in Pennsylvania and New Jersey
- **Implemented 100% remote working**, except critical bench scientists; initiated a global, localized lunch hour free from internal meetings
- **Reinforced flex time/flex schedules** as needed
- **Implemented the “Amicus Family Day”** – a global day off for all employees to safely spend quality time with family and friends; during 2020 employees enjoyed four Amicus Family Days
- **Launched Amicus Cares** to keep employees informed and engaged and maintain business continuity; implemented remote work from home training within first weeks of lockdown
- **Instituted COVID-19 stipends for employees**; employees received two $1,000 stipends during 2020
- **Developed and launched Amicus Learns**, an online learning portal created to encourage career development and advancement
- **Presented global town halls**, medical briefings, and patient events designed to keep employees updated and informed on the evolving climate of the COVID-19 pandemic
- **Launched interactive online social collaboration tools**, such as Microsoft Teams and Yammer, to support employee collaboration and informal connection
- **Implemented Pulse surveys** and published results from employees on how the company handled COVID-19 and its work from home policies and procedures
Amicus teams oversaw additional risk mitigation activities such as the acquisition of additional protective equipment, implementation of new health and safety protocols including screening tools and close contact tracing, and communication of company safety requirements and training.

To protect the health of our employees and maintain business continuity, we adopted work from home policies for those who could do their jobs remotely. We restricted business travel and access to our facilities to essential personnel and services only, and for our field-based employees and where possible, transitioned to virtual engagement with healthcare providers.

A global task force chaired by senior leadership meets frequently to ensure that we are doing everything possible to protect the health of our employees, their families, and our communities while ensuring our medicines and services continue to reach patients. All Amicus regional and affiliate offices continue to follow the guidance of local governments and health organizations, such as the Centers for Disease Control (CDC) in the U.S., the World Health Organization (WHO), and the health agency in each country where Amicus does business.
OUR AWARDS

STANDOUT IN INNOVATION

United Kingdom Prix Galien Innovative Product Medal 2018
Prix Galien USA Best Biotechnology Product Nominee 2020, 2019
Silver Stevie® Winner Most Innovative Company of the Year 2020

EXCELLENCE IN DESIGN

For Philadelphia Center of Excellence:
IIDA PA/NJ/DE Award for Best of Corporate 20,000 SF+2020
IES Illumination Award of Merit 2020
ENR MidAtlantic Best Project Award of Merit in Healthcare 2020

PARTNERSHIP RECOGNITION

BlueJeans First Place Best Collaboration Champion Award 2020
Penn Center for Innovation Deal of the Year 2018
Make-A-Wish Foundation® Corporation of the Year 2015
GOVERNANCE, RISK, & COMPLIANCE

We believe good corporate governance is important to ensure that Amicus is managed for the long-term benefit of our stakeholders. We have adopted a Code of Business Conduct, which applies to all of our officers, directors, and employees, corporate governance guidelines and updated charters for our Audit and Compliance Committee, our Compensation and Leadership Development Committee, our Nominating and Governance Committee, and our Science and Technology Committee (which can be found on our corporate website). These revised governance charters, as well as our Code of Business Conduct which is reviewed and certified annually, provide a framework for the comprehensive oversight of designated risk areas by the Board and its Committees and is an important interface with our Enterprise Risk Management Program.

The Board is equally committed to ongoing Board refreshment and broad diversity of background, gender, skills, and experience. The Board recently introduced a Board skills matrix to ensure diversity, demonstrate the complement of skills on the Board, and identify any gaps to guide future Board refreshment.

Beginning with our Board of Directors and our senior leadership team, we are committed to long-term value driven by the pillars of governance, social responsibility, and integrity across all we do, including employee engagement, clinical and regulatory operations, and eventual access to medicines for patients. Oversight of our Enterprise Risk Management Program is robust, and includes quarterly review by both our internal Global Risk Committee composed of our senior leaders and our Audit and Compliance Committee, which is primarily responsible for reviewing and advising the full Board on all material risks and developments.

Within this risk management framework, we seek to build a sustainable, vibrant risk mitigation culture, which places emphasis on how we do things as much as what we achieve. We recognize the sustainability of our company is linked to our ability to understand and engage all stakeholders in a consistent and meaningful manner, as well as manage risks throughout the organization.
OUR ENTERPRISE RISK MANAGEMENT PROGRAM

The Board, its committees, and our senior leadership team drive and oversee risk reduction through our Enterprise Risk Management Program, which includes established periodic reporting and open lines of communication. The following chart illustrates the oversight responsibilities by the Board for areas in the committees’ areas of expertise under the Enterprise Risk Program.

HOW WE MANAGE RISK

Board of Directors
The full Board has primary responsibility for risk oversight

Management
Management is responsible for the enterprise risk assessment process and the day-to-day management of risks

Global Risk Committee
• Comprised of department leads
• Co-chaired by Chief Compliance Officer and President/Chief Operating Officer

Audit and Compliance
Oversees all matters related to the Enterprise Risk Management Program, as well as financial, compliance, data privacy, and cybersecurity

Nominating and Corporate Governance
Oversees risks related to Board composition, activism, corporate social responsibility, philanthropy, and the company’s position as a global corporate citizen

Compensation and Leadership Development
Oversees risks related to Human Capital including compensation, succession planning, diversity, equity, and inclusion, and pay equity matters

Science and Technology
Oversees pharmacovigilence and risks associated with science, clinical development, regulatory, intellectual property, manufacturing, quality, and supply chain
Safe Harbor

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the inaugural ESG report and programs. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this report may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, statements regarding corporate ESG goals and the attainment of such goals, including as they are impacted by COVID-19 related disruption, are based on current information. The potential impact on operations from the COVID-19 outbreak is inherently unknown and cannot be predicted with confidence and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19, such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain disruptions, limitations on patient access to commercial product or clinical trial sites and investigational product or other clinical study disruptions and disruptions to our employees. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2020. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this report to reflect events or circumstances after its publication date.

OUR COMMITMENT

Demonstrating a commitment to ESG in order to drive resiliency and adaptability across all business units is our continuing promise to our people, our patients, and our communities. By understanding material ESG risks, assessments, and controls, our organization is able to integrate these ESG factors into our decision-making process.
Corporate Headquarters,
Global Research &
Gene Therapy Center
of Excellence

Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia, PA 19104
info@amicusrx.com

International
Headquarters

Amicus Therapeutics UK
LTD
One Globeside
Fieldhouse Lane
Marlow SL7 1HZ
United Kingdom
info@amicusrx.co.uk